EKF Highlights Growing Product Portfolio at AACC 2014 Meeting
|
By LabMedica International staff writers Posted on 04 Aug 2014 |
EKF Diagnostics (Cardiff, UK), a global diagnostics company, is highlighting the expanding product portfolio of its subsidiary Stanbio Laboratory (Boerne, TX, USA) at AACC 2014. EKF Diagnostics has distributors in more than 70 locations around the globe, multinational research and manufacturing facilities, and teams of experienced analysts and engineers in Germany, Ireland, USA, and the UK.
In addition to demonstrating the success of current products, including Stanbio’s ß-hemoglobin (HB) assay technology and EKF Molecular’s Pointman technology, new products will be introduced at AACC. These latest introductions result from EKF’s recent acquisition of Separation Technology Inc. (STI) and DiaSpect Medical.
The diagnostic effectiveness of Stanbio’s enzymatic Beta-Hydroxybutyrate (ß-HB) LiquiColor assay is driving its acceptance in hospital laboratories across the USA as the new standard of care in ketosis testing. More than 850 (20%) of US hospitals are now using the assay for accurate, specific, and quantitative testing of this main ketone produced during ketosis. Consequently, physicians can make better informed clinical decisions. This is changing the way hospitals manage patients displaying symptoms of ketoacidosis.
The liquid-stable LiquiColor ß-HB reagent can be used on open channel chemistry analyzers from twenty different manufacturers. A point-of-care (POC) option is also available in the form of the STAT-Site M ß-HB strip-based testing system.
Since its introduction last year, PointMan DNA enrichment technology has now been shown to be sensitive enough to enable the use of a blood sample to assess the mutation status of a cancer patient. Recent studies have demonstrated that the sensitivity of the technology is far greater than existing polymerase chain reaction (PCR) technology. PointMan can detect 1 mutant gene in 10,000 normal gene copies, whereas competing technologies can only detect 1 in 100. This maximizes the use of smaller biopsy samples and also allows the multiplexing of mutations in a single test rather than many individual tests.
To be previewed at AACC, the palm-sized DiaSpect is a fast HB measurement system giving laboratory quality performance for anemia screening in any environment. Delivering results in 1-2 seconds, the analyzer is CE marked and has been submitted to the US Food and Drug Administration (FDA; Silver Spring, MD, USA) for approval.
The PlasmaPrep-12 centrifuge is ideal for use in both the hospital and laboratory. It is designed for STAT serum/plasma separation and is suitable for coagulation studies. Enabling fast blood separation and easy to use, it is controlled by a microprocessor with four preprogrammed spin times. These include the Platelet Poor Plasma mode providing serum or plasma separations in three minutes and the Platelet Rich Plasma mode providing platelet rich plasma in just 30 seconds.
Julian Baines, CEO of EKF, commented, "EKF now offers a comprehensive and cost-effective product range, as well as meaningfully participating in personalized medicine; an area which is quickly becoming key within the IVD industry.”
Related Links:
EKF Diagnostics
Stanbio Laboratory
In addition to demonstrating the success of current products, including Stanbio’s ß-hemoglobin (HB) assay technology and EKF Molecular’s Pointman technology, new products will be introduced at AACC. These latest introductions result from EKF’s recent acquisition of Separation Technology Inc. (STI) and DiaSpect Medical.
The diagnostic effectiveness of Stanbio’s enzymatic Beta-Hydroxybutyrate (ß-HB) LiquiColor assay is driving its acceptance in hospital laboratories across the USA as the new standard of care in ketosis testing. More than 850 (20%) of US hospitals are now using the assay for accurate, specific, and quantitative testing of this main ketone produced during ketosis. Consequently, physicians can make better informed clinical decisions. This is changing the way hospitals manage patients displaying symptoms of ketoacidosis.
The liquid-stable LiquiColor ß-HB reagent can be used on open channel chemistry analyzers from twenty different manufacturers. A point-of-care (POC) option is also available in the form of the STAT-Site M ß-HB strip-based testing system.
Since its introduction last year, PointMan DNA enrichment technology has now been shown to be sensitive enough to enable the use of a blood sample to assess the mutation status of a cancer patient. Recent studies have demonstrated that the sensitivity of the technology is far greater than existing polymerase chain reaction (PCR) technology. PointMan can detect 1 mutant gene in 10,000 normal gene copies, whereas competing technologies can only detect 1 in 100. This maximizes the use of smaller biopsy samples and also allows the multiplexing of mutations in a single test rather than many individual tests.
To be previewed at AACC, the palm-sized DiaSpect is a fast HB measurement system giving laboratory quality performance for anemia screening in any environment. Delivering results in 1-2 seconds, the analyzer is CE marked and has been submitted to the US Food and Drug Administration (FDA; Silver Spring, MD, USA) for approval.
The PlasmaPrep-12 centrifuge is ideal for use in both the hospital and laboratory. It is designed for STAT serum/plasma separation and is suitable for coagulation studies. Enabling fast blood separation and easy to use, it is controlled by a microprocessor with four preprogrammed spin times. These include the Platelet Poor Plasma mode providing serum or plasma separations in three minutes and the Platelet Rich Plasma mode providing platelet rich plasma in just 30 seconds.
Julian Baines, CEO of EKF, commented, "EKF now offers a comprehensive and cost-effective product range, as well as meaningfully participating in personalized medicine; an area which is quickly becoming key within the IVD industry.”
Related Links:
EKF Diagnostics
Stanbio Laboratory
Latest AACC 2014 News
- Corgenix Diagnostic Ebola Test Research Earns Abstract Award
- Atomo's Blood Test Unveiled at 2014 AACC; Takes Top Award in NY
- Roche Partners with Customers, Redefines Laboratory Value
- Abbott Showcases Innovations, Helps Labs Solve Health Care Challenges
- Sony DADC BioSciences and TSMC Receive AACC Award
- Oncolab Exhibits Pioneering AMAS Cancer Test at AACC
- Thermo Fisher Scientific Showcases Expanded Offering for Clinical Laboratory
- Major Advances in Medical Studies Highlighted at AACC 2014
- Wheaton Offers Unique Solutions for the Clinical Market
- Seegene Reveals New Real-Time PCR at AACC 2014
- AACC Debuts Refreshed Brand Identity
- Mobile Health, Big Data, Antimicrobial Resistance Central to 2014 Meeting
Channels
Clinical Chemistry
view channel
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
Immune checkpoint inhibitors have improved melanoma treatment and extended survival over the past 15 years. However, many patients do not respond, and reliable biomarkers for predicting treatment response... Read more
Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of cases. Acquired ESR1 mutations can cause resistance to endocrine... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more








